● Recruiting

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

Condition: Neovascular Age-related Macular Degeneration · Sponsor: Hoffmann-La Roche

PhasePhase 3

Planned participants250

Who can joinAll sexes, 50 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.

This description comes directly from the study's public registry record.

Talk to the study team

Reference Study ID Number: MR45625 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S.) · global-roche-genentech-trials@gene.com

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Always discuss trial participation with your own doctor first.

Locations (59)

Medizinische Universität Innsbruck	Innsbruck, Austria	Recruiting
Kepler Universitätskliniken GmbH - Med Campus III	Linz, Austria	Recruiting
Landesklinikum Mistelbach	Mistelbach, Austria	Recruiting
Klaudianova Nemocnice - Mlada Boleslav;Ophtalmology dpt	Mladá Boleslav, Czechia	Recruiting
Faculty Hospital Ostrava	Ostrava, Czechia	Recruiting
Ustredni vojenska nemocnice	Prague, Czechia	Recruiting
Aarhus Universitetshospital	Aarhus N, Denmark	Recruiting
Rigshospitalet Glostrup	Glostrup Municipality, Denmark	Recruiting
Institut Ophtalmologique De l Ouest Jules Verne	Nantes, Paris, France	Recruiting
Hopital Edouard Herriot - CHU Lyon	Lyon, France	Recruiting
Clinique Honore Cave	Montauban, France	Recruiting
CHNO des Quinze Vingts	Paris, France	Recruiting

+ 47 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06847542